CDKN2A and head and neck squamous cell carcinoma: However, this testing strategy bears the risk of a potential selection bias as several retrospective studies focusing on the outcome of HNSCC patients based on p16 expression have shown that there is in fact a 10–15% rate of false positive results when only relying on p16 as surrogate marker for HPV-related disease.